US FDA warns of meningitis risk with GSK's Lamictal
This article was originally published in Scrip
Executive Summary
The US FDA has issued a safety warning for GlaxoSmithKline's Lamictal (lamotrigine) over an increased risk of aseptic meningitis associated with its use. The agency is revising the warnings and precautions section of the drug's label and patient medication guide to include information about the risk following reports of 40 cases of the disease in patients taking the drug.